Last reviewed · How we verify

preoperative budesonide inhalation

Fujian Medical University Union Hospital · FDA-approved active Small molecule

Budesonide is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator production.

Budesonide is an inhaled corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator production. Used for Preoperative airway inflammation reduction in patients undergoing surgery, Asthma and chronic obstructive pulmonary disease maintenance therapy.

At a glance

Generic namepreoperative budesonide inhalation
SponsorFujian Medical University Union Hospital
Drug classInhaled corticosteroid
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaRespiratory
PhaseFDA-approved

Mechanism of action

Budesonide acts as a selective glucocorticoid receptor agonist in the lungs, decreasing production of inflammatory cytokines, chemokines, and adhesion molecules. When administered preoperatively via inhalation, it reduces airway hyperresponsiveness and inflammation, potentially decreasing perioperative respiratory complications in susceptible patients.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: